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ABSTRACT 
 
ASHLEY ELIZABETH NOBLIN: Exploration of Compound Viability as an Organ-
Selective Anti-Metastatic Therapeutic Treatment for Triple Negative Breast Cancer 




 Phenformin and metformin are compounds that are currently used to treat Type II 
Diabetes and have been shown to suppress breast cancer metastasis. These compounds 
were tested, after extensive research and screening of current approved oncology drugs, 
in various experiments with the cell lines MDA-MB-231, LM, and BoM, with MDA-
MB-231 being the parental cell line, LM being the lung metastatic line, and BoM being 
the bone metastatic line. The cells were treated with compound addition at various 
concentrations and subject to a two-day concentration response viability study in order to 
determine any inhibitory effects, followed by a five-day assay in order to determine the 
effect of extended exposure duration. Phenformin was found to act inconsistently at 
physiologically relevant concentrations. Metformin, however, showed significant 
increases in inhibitory effects when the cells were exposed to the compound for a longer 
duration. Clonogenic assays were performed to confirm the inhibitory effects of the 
compounds. Further pharmacology research needs to be completed, but both compounds 
show potential to serve as an antimetastatic therapeutic treatment option and thus 
improve the prognosis of breast cancer patients.  
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INTRODUCTION 
 
In recent years, there has been a steady decline in the number of cancer incidences 
in developed countries. This decrease in disease rate can be attributed to new 
technologies, funding for research, new technique discoveries for treatment, and 
education for disease prevention (Cancer Research UK, 2011). Despite this success in 
furthering the understanding of non-invasive cancer and how it works, little is known 
about metastasis-associated disease relapse, which accounts for over 90% of cancer 
mortality (American Cancer Society, 2012). Metastatic cancer cells seem to be extremely 
invasive and unpredictable, due to their tendency to develop resistance to the treatments 
and technologies available as they spread to vital organs. With no current treatments that 
effectively curb this spread, there is an urgent need for a more specific drug discovery 
approach (American Cancer Society, 2012). One area of research in which this field is 
rapidly underway is drug discovery targeting metastatic breast cancer.  
Metastatic breast cancer affects roughly one in eight American women in their 
lifetime, and is one the most commonly diagnosed form of cancer with the highest rate of 
mortality behind lung and skin cancer (American Cancer Society, 2012). Breast cancer 
can present in various forms, each with its own unique molecular makeup and 
mechanisms. These subtypes include expression of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). 
When a breast cancer cell is negative for all of these receptors, it is considered a triple-
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negative form of breast cancer and has a highly unfavorable prognosis due to the 
likelihood of metastasis to several vital organs, including the lungs, bone, brain, and liver, 
highlighted in Figure 1 (American Cancer Society, 2012). Triple-negative breast cancer, 
namely the human cell line of MDA-MB-231 and its metastatic lines to the bone and 
lung, are the focus of this research. 
                           
Figure 1. Locations commonly associated with breast cancer metastasis.  
From National Breast Cancer Foundation, Inc. 2015. 
 
 
Scientists for centuries have described cancer metastasis using the “seed and soil” 
model (Kang, 2013). This model suggests the cancerous cells themselves represent the 
seeds, while the organs to which these cells metastasize represent the soil. As the model 
suggests, the seed must be near the soil and the soil must be a viable environment for the 
seed to grow (Kang, 2013). The process by which this occurs begins with the primary 
tumor. Cells from the primary tumor break away from the mass and begin to intravasate 
into circulatory or lymphatic vessels. Once they have completely penetrated the vessels, 
they enter the bloodstream, travel to target organs, become lodged in the capillaries 
surrounding that organ, and extravasate through the vessel (McGee, 2010). From this 
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point, the cells must adapt to the new tissue environment and begin replicating in order to 
form the secondary lesions characteristic of metastasis. This process is represented by 
Figure 2. 
 
Figure 2. Overview of the key molecular events of metastasis. 
From Sharon F. McGee. Royal College of Surgeons in Ireland Student Medical 
Journal 2010; 3:56-60 
 
 
 Although it was previously assumed that breast cancer cells could not begin 
metastasis until the primary tumor was fully established, current research has shown that 
these cells have the capacity to survive in circulation and disseminate to distant organs 
even before the primary lesion is formed (Kang, 2013). If these disseminated tumor cells 
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gather to even the minute size of less than 2 mm, they began to receive a vascular blood 
supply and can be considered a secondary site (Kang, 2013). As mentioned before, this 
metastasis for breast cancer typically occurs to the lungs, bone, brain, and liver. The 
reasons for these specific locations being favorable are not fully understood, however it 
has been tied to the environment that these organs provide to the proliferative cells 
(American Cancer Society, 2012). This is what gives breast cancer its identity as the 
second most common malignant disease in Western women next to skin cancer and why 
researching this metastasis is such a growing area (Weigelt, 2005). Metastasis research 
has shown great strides in identifying genes, microRNAs, and molecular mechanisms that 
aid in the proliferation of cancer cells, however the metabolic alterations associated with 
metastasis is a relatively unexplored area of inquiry (Weigelt, 2005).  
 The metabolic requirements for cellular proliferation have been shown to be very 
different in cancerous versus non-cancerous cells (Vander Heiden, 2009).  Healthy cells 
are exposed to an adequate amount of oxygen and nutrients and do not uptake these 
supplies excessively due to control mechanisms within the body, preventing uncontrolled 
proliferation (Vander Heiden, 2009). Normal cells metabolize using the process of 
oxidative phosphorylation in the presence of oxygen. Glucose is metabolized to carbon 
dioxide by the oxidation of pyruvate in the mitochondria in order to produce NADH 
(nicotinamide adenine dinucleotide). The NADH then fuels the process of oxidative 
phosphorylation, which typically produces about thirty-six moles of adenosine 5’-
triphosphate (ATP). This is a highly effective means of creating energy for the cell, and it 
produces minimal amounts of lactate (Vander Heiden, 2009).  
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 Cancerous cells, however, have a different means of metabolism. These cells, 
having acquired of oncogenic mutations, overcome the natural control mechanisms 
(Vander Heiden, 2009). This results in an increased uptake of nutrients, specifically 
glucose, in order to exceed the bioenergentic needs of the cell to promote cell growth and 
proliferation.  These cells do this by the process of aerobic glycolysis, a generally 
inefficient way to produce cellular energy (Warburg, 1927). Even in the presence of 
adequate oxygen, only about 5% of glucose is used for the process of oxidative 
phosphorylation, 10% is used for biosynthesis, and the majority 85% is converted into 
lactate. This only produces about four moles of ATP per mole of glucose (Vander 
Heiden, 2009). Scientists for years have questioned the nature of this metabolic change to 
anaerobic glycolysis, also known as the Warburg effect, that has become a hallmark of 
cancerous cells. 
One hypothesis was that mutations in the cells themselves caused a defect in the 
mitochondria, which would limit the cells ability to effectively carry out oxidative 
phosphorylation (Vander Heiden, 2009). However, research has shown that the 
mitochondria are not compromised in most cancer cells. One possibility that researchers 
are further exploring involves the idea that the excess production of lactate allows carbon 
to be incorporated more rapidly into the biomass, which would promote rapid cell 
division and proliferation (Vander Heiden, 2009). 
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Figure 3. Schematic representation of the differences in cellular metabolisms. 
From Matthew G. Vander Heiden. Understanding the Warburg Effect: The Metabolic 
Requirements of Cell Proliferation. 2009. 
 
 
 As shown in Figure 3, aerobic glycolysis produces ATP in an amount in between 
that produced in anaerobic glycolysis and oxidative phosphorylation (Vander Heiden, 
2009). From this information, it can be understood that metastatic cells must maintain a 
glycolytic metabolism (~4 ATP mol ATP/mol Glc), or adopt a metabolic pathway 
mirroring oxidative phosphorylation (~36 mol ATP/mol Glc) in order to produce an 
adequate amount of ATP to survive and proliferate in the secondary tissue. Further 
extrapolating from this idea, it can be proposed that different drugs used for treatment 
aimed to promote anti-proliferative effects may target and disrupt different metabolic 
mechanisms determined by the specific pathways that the metastatic cells adopted. 
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 Current treatments for breast cancer include surgery, radiation therapy, 
chemotherapy, hormone therapy, and molecular-targeted therapies (American Cancer 
Society, 2012). All of these therapies are based around the idea that every cancer is as 
unique as each patient. Thus, each therapy and approach must be tailored to maximize the 
individual benefits in order to see results (American Cancer Society, 2012). Although 
these treatment plans are beneficial, finding a more curative option is the goal of new 
antimetastatic drug discovery research. One area of this research involves the exploration 
of natural products as a source of new drug therapies (Cragg, 2013). Natural products are 
chemical compounds produced by living organisms and have recently been deemed the 
single largest source of market drugs, when also taking into consideration their 
derivatives (Cragg, 2013). Given the urgent need for this new generation of possible anti-
metastatic drugs, a library of approved oncology drugs and natural products were 
examined in order to select drugs for target organ-selective inhibitory activities. From 
this data, two natural product drugs, metformin and phenformin, were selected to further 
explore any anti-proliferative phenomenon seen when tested with breast cancer metastatic 
cell lines. 
 Metformin and phenformin are classified as biguanide drugs that are commonly 
used in the treatment of diabetic patients, namely individuals with Type II Diabetes (Liu, 
2015). Type II Diabetes is characterized by insulin resistance, which is when the body 
makes insulin but cannot metabolize it correctly. By a study done by Lugaro and 
Ginnattasio in 1968, it was suggested that these biguanide drugs might possess anti-
proliferative effects in cancer patients (Lugaro, 1968). As patients with diabetes were 
treated with metformin, they experienced a 31% decrease in the general risk of cancer 
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incidences compared to those using other therapeutic techniques. Retrospective studies 
then showed an association between biguanide use and improved cancer-related mortality 
(Lugaro, 1968). This led to studies of antitumor activity of these drugs, and created the 
question of whether or not metformin and phenformin could be used as an anticancer 
agent in non-diabetic patients as well. Most of this research has been done in regards to 
metformin (Liu, 2015). 
Metformin (N’, N’-dimethylbiguanide), shown in Figure 4, has been studied 
more extensively than phenformin, its related compound. This is due to its wide usage in 
diabetic patients, which has deemed metformin a generally safe and well-tolerated drug 
by patients (Liu, 2009). In clinical studies, metformin has been shown to promote anti-
proliferative effects and apoptosis, while inhibiting colony formation in triple-negative 
breast cancer (Liu, 2009). It has also been found that triple-negative breast cancer is more 
common in women with obesity or Type II Diabetes. For this reason, metformin has been 
a relevant and aggressive area of treatment study (Zordoky, 2014).  
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 Phenformin (phenethylbiguanide) is much less tested and understood than its 
metformin counterpart (Liu, 2015). This is due to the fact that phenformin has been 
shown to be highly toxic in patients with renal failure, leading to lactic acidosis. Despite 
its apparent high toxicity, it has been shown that it is a much more potent antitumor agent 
(Liu, 2015). Phenformin is represented in Figure 5. 
 
	  




	   Both metformin and phenformin are thought to halt triple-negative breast cancer 
metastasis by inhibiting mitochondrial function, thus limiting the amount of ATP able to 
be created to use for division and growth. The exact mechanism behind this process is 
unknown, however (Liu, 2015). The properties of these biguanide drugs are represented 
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PROPERTIES OF RELEVANT BIGUANIDE DRUGS 
 








MOLECULAR WEIGHT 165.62 241.72 
SOLUBILITY 50 mM in DMSO 3.8 mg/mL in Isopropanol 
STABILITY Stable Stable 
STORAGE 
CONDITIONS 
-20 °C -20 °C 
 
Figure 6. Chemical properties and conditions of metformin and phenformin. 
From Sigma-Aldrich. 
 
 The potential antitumor effect of metformin’s and phenformin’s to triple-negative 
cell lines make it an interesting and relevant area of research. For this reason, this first 
study will focus on the effects that these two drugs have on three different cell lines: 
MDA-MB-231, BoM, and LM. MDA-MB-231 represents the parent human breast cancer 
cell line, BoM represents the bone metastatic cells, and LM represents the lung metastatic 
cells. LM is the lung metastatic cell line. The first of the three represents the parent cell 
line for triple-negative human breast cancer and will serve as a baseline in order to 
compare and contrast how the two drugs interact with primary site cells. BoM and LM 
both represent metastatic cell lines, the first of which being metastasis to the bone and the 
later being the lung. These two organs are significant, because it is thought that they 
harbor and grow disseminated tumor cells by different mechanisms, which would suggest 
different results between the two sites. 
 The objective of this study was to identify the differences in potency between 
metformin and phenformin in the three chosen triple-negative cell lines in order to test 
their viability as an organ-selective antimetastatic therapeutic treatments. The different 
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mechanisms that the organs have adopted to promote anti-proliferative effects, along with 
the different chemical properties and mechanisms of the two drugs, served as a means to 
predict which combination of cell line and drug would be most successful in the 
treatment of metastatic breast cancer. After compound research and screening methods, 
these questions were explored by performing various cell viability assays to determine 
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MATERIALS AND METHODS 
 
I. NCI 60 Cell-line Assay  
Developmental Therapeutics Program/National Cancer Institute 
 In the early 1990s, the Developmental Therapeutics Program (DTP) of the 
National Cancer Institute (NCI) created a system to screen for potential new anti-cancer 
drug treatments. This method uses a panel of sixty different human tumor cell lines 
representing nine different tissues types in order to characterize different compounds 
based on their ability to inhibit the growth of or kill tumor cells. This provided a database 
of FDA-approved anti-cancer agents based on their compound sensitivity and molecular 
mechanism that was then subject to screening by the NCI in order to calculate specific 
growth inhibition data.  
 Using the 60 cell-line assay data available on the NCI website, a spreadsheet was 
created to identify these growth inhibition values for three panels of breast cancer cell 
lines to review its drug sensitivity to approved oncology drugs via concentration-response 
data. The breast cancer cell lines used were MCF-7, T47D, and MDA-231, while growth 
inhibition values included were GI50, TGI, and LC50.  
	  
	  
II.	  Screening	  Data	  
National	  Cancer	  Institute,	  Approved	  Oncology	  Drugs
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From the assay data gathered in the previous section of this experiment, Dr. Yu-
Dong Zhou from the University of Mississippi completed screening experiment in order 
to hone in on the MDA-MB-231 cell line and particular sites of metastasis associated 
with the parental line. The lung (LM), bone (BoM), and brain (BrM-2a) metastatic sites 
were screened, along with two other non-triple- negative cell lines, T47D and MCF-7, 
which were represented in the 60-cell line assay. 
The screening methodology began with seeding the cells in 96-well plates 
followed by an incubation period of one day. In order to determine a time-zero density, 
some plates were processed at this time to serve as a control for the screening. The 
remaining plates had compounds added to them, including media controls, 0.5% dimethyl 
sulfoxide (DMSO), 1 µM Paclitaxol, and 10 µM cycloheximide (CHX) and all were 
tested at a final concentration of 1 µM. At this point, the cells were fixed, stained with 
sulforhodamine B (SRB), and growth inhibition could be calculated for the data to 
became available at the NCI website for approved oncology drug research.	  
	  
III. Pilot Experiment with BoM 
 
Natural Product Retrieval 
 
 The two natural product compounds to be used in these experiments, phenformin 
and metformin, were purchased from the Sigma-Aldrich Company and stored at -20 °C in 
the Department of BioMolecular Sciences repository, University of Mississippi, 
University, MS.  
 
Cell Culture and Seeding for Viability 
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 In order to practice the techniques and procedure protocols, BoM cells seeded 
from a previous individual’s experiment were used in order to prepare the ninth passage 
(P9) of split cells. The eighth passage (P8) of cells were on a 10 cm diameter plate at a 
density of 1.2 x 106 cells and were ready to be trypsinized. After removing the plate from 
the incubator, the media was aspirated into a waste container and the cells were washed 
with 10 mL of 1 x Dulbecco’s phosphate-buffered saline (DPBS, Company: Gibco, 
Catalog #: SH30028.02). The solution was mixed in the dish before aspirating the liquid 
again, and 1.8 mL of Trypsin (Company: Gibco, Catalog #: 250200-056) was added into 
the plate followed by an incubation period of five minutes. This time period allows for 
the trypsin, a proteolytic enzyme, to cut the extracellular proteins on the cells that are 
adhering them to the plate in order to remove the cells from the cultures surface. 
Following the short incubation period, 10 mL of Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F-12) with L-glutamine media was added, supplemented 
with 10% fetal calf serum (FCS) and penicillin/streptomycin (P/S) antibioties. This was 
added in order to neutralize the reaction to prevent excessive cell denaturation.  
Next, a 20 mL pipet was used in order to place a sample of the culture into a 
hematocytometer to count the cell density. Two large squares consisting of sixteen 
individuals units were counted for cell number under a microscope and averaged 
together. It was found that the relative cell count was 106 x 104 cells/mL, which meant 
that approximately 7 mL of media should be used for seeding. This would place the total 
cell count per well about 300,000 cells/mL for a total volume of 10.6 mL. This mixture 
was put into a reservoir and 100 µL/well was filled into the 96-well clear-bottomed plate 
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using a multi-channel pipet. The seeded 96-well plate was then placed in the incubator 
overnight at 37 °C. 
The next generation was also prepared for overnight incubation by pipetting 1 mL 
of the P8 BoM cell line into a new culture plate with 10 mL of media. The approximate 
1.0 x 106 cells were washed with 5 mL of DPBS and placed in the incubator.  
 
Concentration-Response Viability Study with BoM 
 The next day, the cells were observed under a microscope and seemed to be 
adhered to the plate at a relatively low density. Able to proceed to the next step of the 
experiment due to the health of the cells, stock solutions of phenformin and metformin 
were prepared. Phenformin (6.45 mg) was dissolved in 541 µL of double distilled water 
(ddH2O) in order to get 50 mM of stock solution. The stock solution (100 µL) was mixed 
with 400 µL of ddH2O in order to obtain 10 mM stocks, resulting in 1 mg phenformin 
into 0.4137 mL of solvent. The total solution was then aliquoted into two separate vials at 
a volume of 150 µL per vial. The stock solution for metformin was prepared by weighing 
7.15 mg of metformin and adding 451.86 µ/L of ddH20 in order to obtain the 100 mM 
stock solution. This resulted in 1 mg of metformin into 0.0604 mL of solvent, which was 
then aliquoted into three vials at a volume of 130 µL each. Both stock solutions were 
stored at -20 °C. 
 Next, the compounds were prepared into working solutions for testing by 
planning the plate layout and dilution factors based on their physiological relevance. It 
was decided that phenformin would be tested at final concentrations of 0.03, 0.1, 0.3, 1.0, 
3.0, and 10 µM with a starting stock solution concentration of 2.8 µL into 1397.2 µL of 
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the DMEM/F-12 media (P/S, no FCS). A summary of the preparations is shown in 
Figure 7. 
 










P/S, no FCS) 
10 µL 2.8 µL   1397.2 µL 
3 µL  10 µM 360 µL 840 µL 
1 µL  10 µM 100 µL 900 µL 
0.3 µL  3 µM 100 µL 900 µL 
0.1 µL  1 µM 100 µL 900 µL 
0.03 µL  0.3 µM 100 µL 900 µL 
 
Figure 7: Summary of Phenformin Preparation for Pilot Experiment with BoM. 
 
 Metformin was tested at final concentrations of 1.0, 3.0, 10.0, 30.0, 100.0, and 
300.0 µM. Its serial dilution preparation is shown in Figure 8.  
 










P/S, no FCS) 
300 µL 8.4 µL   1391.6 µL 
100 µL  300 µM 360 µL 720 µL 
30 µL  300 µM 100 µL 900 µL 
10 µL  100 µM 100 µL 900 µL 
3 µL  30 µM 100 µL 900 µL 
1 µL  10 µM 100 µL 900 µL 
 
Figure 8: Summary of Metformin Preparation for Pilot Experiment with BoM. 
 
 These working solutions were prepared at 2x the final concentration in order to 
reduce variation. Further reducing variation and acting as a positive control, CHX was 
prepared by adding 30 µL of 10 mM stock solution in DMSO into 1470 µL of media. 
Media controls were also added into the plate layout to control for results. After all of the 
compounds were added to the plate in a serial dilution fashion, the samples were mixed 
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on a plate vortexer for approximately two minutes. The plate was then placed in the 37 
°C incubator to begin the 48-hour incubation period.  
 After the incubation period, the plate was removed from the incubator. The 
conditioned media (100 µL) was pipetted out of each well, and 100 µL of 20% 
trichloroacetic acid (TCA) in 1x phosphate-buffered saline (PBS) was adding into each 
well. This step denatures the proteins in the FCS media in order to fix them to the plate. 
The plate was then placed in the incubator at 4 °C for one hour in order to bring this 
process to completion. After this time period, the media and TCA from the wells were 
dumped out of the plate into the sink, the plate was washed four times with tap water and 
placed upside down in order to air dry overnight.  
 The next day, the wells were stained with 0.4 % SRB by adding 75 µL into each 
well and were set aside for 10 minutes to allow the stain to set in. After this time, the 
wells were washed four times were 1% acetic acid and placed to air dry over night. 
 At this point, the plate was ready to be read in order to obtain results for the 
concentration response viability practice study. Trizma base (100 µL of 10 mM) was 
added per well, which extracts the red dye in order to accurately read the plate. The plate 
was placed on a vortexer in order to shake and evenly distribute the contents. Using a 
BioTek Synergy H1 microplate reader at a reference wavelength of 630 nanometers and a 
measurement wavelength of 490 nanometers, the plate was inserted for reading. It was set 
on normal speed, with the temperature and shaking function turned off. The data was 
recorded and used in order to calculate the percent inhibition. 
 
IV. Two-Day Assay with MDA-MD-231, LM, and BoM 
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Cell Line Retrieval and Preparation 
 In order to further understand the specificity and molecular basis for parental cell 
line breast cancer metastasis, researchers Massague and colleagues introduced MDA-
MB-231 cells into an animal model in order to isolate organotropic subclones. These 
subpopulations were all separately introduced into different animal models in order to 
isolate the individual cell lines of LM and BoM by in vivo selection.  These cells lines 
were then received from Dr. Kounosuke Watabe from Wake Forest University as part of 
an ongoing research collaboration between Dr. Watabe and Drs. Nagle and Zhou at the 
University of Mississippi. All cells were used within twenty passages.  
 The cells were put into vials with a special media, centrifuged, processed through 
the removal of supernatant, and aliquoted into three separate cryogenic vials. The vials 
were then frozen in liquid nitrogen in the National Center for Natural Products Research 
repository, University of Mississippi, University, MS. The passage number and dates in 
which the individual cell lines were frozen are as follows: MDA231, P2, 12/20/14: 
MDA231-LM, P1, 9/10/14: and MDA231-BoM, P3, 1/13/15. 
 The three vials were placed in a 37 °C incubator in order to unfreeze them which 
the media and plates were prepared. Three plates were labeled, one for each cell line, and 
9 mL of 10% FCS, DMEM media was added to each. After the cells were ready to be 
removed from the incubator, the contents of each cryogenic vial was individually pipetted 
into its respective plate, mixed around to evenly disperse the contents, and placed in the 
incubator for a length of two nights. 
 
Seeding for Viability  
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 Two days later, the media was changed in all plates and placed back in the 
incubator over the weekend. The cells were then observed in order to determine if they 
were ready to be seeded for viability. Upon MDA-MB-231 looking confluent and ready 
for seeding, the media was aspirated and cells were washed with 5 mL of DPBS. This 
was then aspirated, followed by the addition of 1 mL of trypsin and incubation. After five 
minutes in the incubator, the plate was removed and 10 mL of the culture media was 
added. Cell counts were then obtained using the hematocytometer, which ended up being 
around eight million cells. Upon calculation, it was determined that the cells would be 
diluted in a total volume of 10.7 mL, consisting of 4 mL of cells from the culture plate 
and 6.7 mL of media. This mixture was put into a reservoir, and 100 µL was pipetted into 
each well of a 96-well plate. The plate was then placed in the incubator.  
 The LM and BoM cell lines underwent the same protocol under different 
concentrations of cells and media based on the cell count. The LM 96-well plate was 
prepared by pipetting 100 µL of a mixture of 2.5 mL of cells and 9.5 mL of media into 
each well. BoM was prepared using a mixture of 4 mL of cells and 4.3 mL of media. All 
plates were prepared and placed in the incubator overnight.  
 
Two-Day Concentration Response Viability Study 
 The next day, the cells were observed in order to see in the viability experiment 
could proceed. All cells in the 96-well plate were evenly distributed and at an adequate 
density, so the dilution calculations were prepared. The layout of the 96-well plates to be 
used for all three cell lines was designed, utilizing columns 1-8. The plate layout with 
stock and media dilution factors are shown in Figure 9. 
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 Columns 1-4: Phenformin Columns 5-8: Metformin 
A Media Control Cyclohexamide Control, 10 µM 
B 0.03 µM 
150 µL stock, 1350 µL media 
1 µM 
150 µL stock, 1350 µL media 
C 0.1 µM 
150 µL stock, 1350 µL media 
3 µM 
150 µL stock, 1350 µL media 
D 0.3 µM 
150 µL stock, 1350 µL media 
10 µM 
150 µL stock, 1350 µL media 
E 1 µM 
150 µL stock, 1350 µL media 
30 µM 
150 µL stock, 1350 µL media 
F 3 µM 
150 µL stock, 1350 µL media 
100 µM 
3 µL stock, 1497 µL media 
G 10 µM 
3 µL stock, 1497 µL media 
300 µM 
9 µL stock, 1491 µL media 
H 30 µM 
9 µL stock, 1941 µL media 
Media Control 
 
Figure 9: Plate Layout for Two-Day Viability Study. 
 
Aliquot tubes were placed on a rack, and media was added to them in order to 
begin the serial dilution. The dilution was designed for a stock solution for phenformin of 
10 mM in ddH20 and a stock solution for metformin of 100 mM in ddH20. After the 
dilution was complete, 330 µL of phenformin solution at each concentration was added to 
a workin Luciferase plate, and 100 µL at a time was pipetted into three separate 96-well 
plates, always going from low to high concentration to reduce error. The phenformin 
solution was pipetted into columns one through four, while the metformin solution was 
prepared in the same way and added to columns five through eight. The plates were then 
vortexed and placed in the incubator. 
 After a 48-hour incubation period, the plates were removed and 100 µL of the 
conditioned media was removed from each well, 100 µL of 20% TCA in 1xPBS was 
added, and plates were incubated for one hour. Following incubation, the supernatant was 
removed and the plates were washed with tap water four times before allowing them to 
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dry overnight. The next day, the plates were stained and washed in the same fashion as in 
the pilot experiment and left to dry overnight.  
 The next day, the plates were read by adding 100 µL of Trizma Base, shaking 
them on a vortex, and inserting into the plate reader one at a time. The reader used was 
SpectraFluor Plus (Tecan), with a measurement wavelength of 492 nanometers and a 
reference wavelength of 620 nanometers. The temperature was set to 21.7 °C, shake was 
added for 5 seconds, and the reading occurred in three flashes per plate. Data was 
recorded and used in order to calculate percent inhibition and control. 
 
V. Five-Day Viability Study  
Cell Lines MDA-MB-231, LM, and BoM 
In order to gain more accurate results, it was decided to proceed with a five-day 
viability study in order to allow more adequate and extensive time for the compounds to 
affect the cells. Cells from cell lines MDA-MB-231, LM, and BoM were gathered from 
storage in the Natural Product Center at the University of Mississippi and prepared in an 
identical fashion to the cell lines in the two-day viability study. The plates were mixed, 
incubated overnight, and had their media changed the following day before a three-day 
incubation period. After incubation, plates were trypsinized and subject to media change 
due to the fact that they appeared very stressed and not fully confluent. After 
trypsinization, cells remained as a low density, so cell lines were split at different ratios 
based on their specific growth rate and properties in order to proceed with viability.   
 The BoM cells were split at a high ratio of 1:1:2 due to its slow growth rate and 
low cell count. The seeded passage (P2) of BoM was trypsinized following typical 
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protocol, and 20 µL of the P2 contents was pipetted into two dishes. The P2 contents (40 
mL) were pipetted into a larger flask in order to increase the surface area for cell 
proliferation and increase cell density. MDA-MB-231 was subject to a 1:3 split after 
trypsinization, with 40 mL of the P2 contents being pipetted into the flask. Due to its fast 
growth rate, LM was split twice at a 1:10 ratio and a 1:5 ratio. The original P1 plate 
contents were placed into a flask and subject to trypsinization. Media (9 mL) was added 
to the 1:10 split plate, followed by the addition of 1 mL of trypsinized cells, and 8 mL of 
media was added to the 1:5 split plate, followed by the addition of 2 mL of trypsinized 
cells. All prepared plates and flasks were placed into the incubator for 48 hours.  
 Following the incubation period, the plates were trypsinized, counted for cell 
density, and seeded into 96-well plates at a density of 3x106 cells per well. Following 
overnight incubation, a serial dilution was prepared for each cell line using the 
phenformin and metformin stock solutions. The plates were then incubated for a total of 
72 hours before the media and compounds were changed and plates were maintained in 
37 °C incubation conditions.  
 On day five of the experiment, it was noted that the plate media had turned a 
yellow color, which signaled that the cells were stressed. To avoid loss of results, it was 
decided to stop the viability study after five days and proceed to fix and stain the cells in 
each plate. After allowing a day for the cells to dry after staining, the plates for MDA-
MB-231, LM, and BoM were read at a wavelength of 490/620 nanometers. Data was 
recorded and used in order to calculate percent inhibition to interpret results.  
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VI. Clonogenic Assay 
Cell Lines MBA-MB-231, LM, and BoM 
In addition to the concentration response viability study, it was decided to proceed 
with preparing plates for a colonogenic assay in order to study the effect of the agents on 
colony cell survival and proliferation. One six-well plate was prepared for each cell line 
by seeding cells at a concentration of 300,000 cells per well and 2 mL of DMEM media 
with no FCS, supplemented with antibiotics. The concentrations of the compounds added 
were chosen based on taking into consideration the physiological relevance for both 
compounds and using this concentration followed by the next highest concentration to 
compare cytotoxicity. The plate layout is shown in Figure 10. 
 
MEDIA CONTROL PHENFORMIN: 3 µM PHENFORMIN: 10 µM 
CHX CONTROL METFORMIN: 30 µM METFORMIN: 100 µM 
 
Figure 10: Plate Layout for Clonogenic Assay  
 
Once prepared, the plates were maintained at 37 °C and were subject to media 
change after four hours and again after four days. After checking the plates following this 
incubation period, it was noted that some signs of contamination were evolving, so it was 
decided to proceed by fixing the plates earlier than anticipated. The following day, the 
media was aspirated, the cells were washed, and cells were fixed by the addition of 1 mL 
of cold methanol to each well. Plates were immediately placed in a -20 °C environment 
for five minutes before the methanol was removed and plates were stained. Staining was 
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completed by the addition of 1 mL of 0.1 % crystal violet in PBS to each, followed by the 
addition of 1 mL of 0.1% crystal violet in 20% ethanol for better results. The plates were 
then washed with PBS and images of the stained colonies were taken in order to compare 
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RESULTS 
 
I. 60-cell line Assay 
Developmental Therapeutics Program/National Cancer Institute  
 The spreadsheets created were done so in order to review the drug sensitivity of 
the MCF-7, T47D, and MDA-231 cell lines to approved oncology drugs by identifying 
the GI50, TGI, and LC50 growth inhibition values from the 60 cell-line assays. 
 Relative to the time zero control noted in the screening methodology, the GI50 
value is the concentration of a compound that causes 50% growth inhibition. The results 
for the three cell lines are shown in Figure 11.
 
DRUG NAME MCF-7 T47D MDA-MB-231 
Hydroxyurea -3.5 N/A -2.6 
Allopurinol -3.6 -3.2 -3.8 
Fluorouracil -5.8 -4.1 -3.3 
Thioguanine -6.1 -5.7 -5.3 
Mercaptopurine -5.7 -5.2 -4.3 
Mechlorethamine hydrochloride -5.8 N/A -4.8 
Thiotepa -4.5 -3.7 -3.5 
Aminolevulinic acid hydrochloride -4 -4 -4 
Temozolomide   -4 -4 -4 
Busulfan -3.6 -3.6 -3.6 
Altretamine -3.8 N/A -3.8 
Floxuridine -6.6 -4.2 -4 
Methoxsalen -4 -4 -4 
Lomustine -4.4 N/A -6 
Azacitidine   -6 -6.1 -6.1 
Decitabine   -3.8 N/A -4.7 
Carmustine   -4.2 -4.1 -4.2 
Cyclophosphamide   -3.6 N/A -3.6 
Uracil mustard -4.8 N/A -4 
Cytarabine hydrochloride -6.8 -3.3 -3.5 
Thalidomide   -4 -4 N/A 
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Procarbazine hydrochloride -3.3 N/A -3.3 
Streptozocin -3.3 N/A -3.1 
Cladribine -5.4 -5.2 -4.1 
Ifosfamide -3.4 N/A -3.3 
Cisplatin -5.4 -4.5 -4.3 
Tretinoin -4.4 -6.3 -4.3 
Dexrazoxane -4.7 -4.2 -3.5 
Pentostatin -3.4 -3.3 -3.3 
Nelarabine   -2.4 -2.3 -2.3 
Vorinostat   -5.6 -6.3 -5.6 
Exemestane   -4.8 -4.3 -4.5 
Anastrozole   -2.6 -2.2 -3.3 
Letrozole   -2.3 -2.3 N/A 
Lenalidomide   -4 -4 -4 
Pomalidomide -4 -4 -4 
Chlorambucil   -4.4 -4 -3.7 
Mitomycin  -6.7 -5.5 -5 
Mitotane -4.7 N/A -4.7 
Clofarabine   -6.8 -5 -5.3 
Pipobroman -4.3 N/A -4 
Megestrol acetate -4 -4 -4 
Bendamustine hydrochloride -4.2 -4.3 -4.2 
Fludarabine phosphate   -4.1 -4.1 -3.5 
Bortezomib   -8 -8 -8 
Capecitabine  N/A -2 N/A 
Celecoxib -4.8 -4.8 -4.8 
Sunitinib  -5.7 -4.8 -5.5 
Axitinib -4.9 -5.4 -4.3 
Mitoxantrone -8 -7.3 -6.7 
Pemetrexed -7.8 -4 -5 
Gefitinib   -5 -5.2 -4.9 
Vismodegib -4.5 -4.5 -4.7 
Crizotinib   -6.3 -5.8 -5.8 
Methotrexate   -7.4 -4 -3.7 
Topotecan hydrochloride -7.8 -7.9 -5.2 
Dasatinib   -4.9 -6.7 -7.8 
Pazopanib hydrochloride -5.2 -5.4 -5.2 
Imatinib -4.7 -4.7 -4.7 
Sorafenib -5.6 -5.8 -5.9 
Raloxifene -7.1 -5.2 -5 
Afatinib -5.7 -6.1 -5.9 
Pralatrexate   -8 -4 N/A 
Enzalutamide  -4.6 -4.7 -4.8 
Vandetanib -5.7 -5.8 -5.8 
Vemurafenib   -5.4 -5.3 -5.5 
Regorafenib  -5.6 -5.6 -5.8 
Idarubicin hydrochloride -8 -7.8 -7 
Nilotinib  -5.6 -5.2 -5.7 
Ixabepilone  -8 -8 -8 
Romidepsin   -8 -8 -8 
Omacetaxine mepesuccinate -8 -7.5 -7.1 
Ponatinib  -6.1 -6.2 -6.7 
Cabozantinib  -5.4 -5.4 -5.5 
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Bosutinib  -5.6 -5.5 -5.6 
Daunorubicin hydrochloride -8 -7.3 -6.9 
Doxorubicin hydrochloride -7.6 -7.2 -6.3 
Etoposide   -5.8 N/A N/A 
Tamoxifen citrate -5.7 -5.5 -5.4 
Epirubicin hydrochloride N/A -7 -6 
Estramustine phosphate sodium -4 -4.2 -4.6 
Lapatinib  -5.7 -5.5 -5 
Irinotecan hydrochloride -5.2 -4.6 -4.4 
Fulvestrant -8 -6.1 -4 
Trametinib  -4.9 -4.8 -6.9 
Dabrafenib mesylate -4.6 -4.6 -5.1 
Teniposide -7.5 N/A -5.9 
Valrubicin N/A -6.3 -5.5 
Carfilzomib  -8 -7.9 -7.9 
Docetaxel   -8 N/A -8 
Cabazitaxel   -8 -8 -7.7 
Paclitaxel   -8 -7.1 -8 
Vinblastine sulfate   -8 -4.7 -8 
Vincristine sulfate   -7 -3.7 -7 
Sirolimus -7.4 -7.3 -5.2 
Everolimus   -8 -8 -4.9 
Dactinomycin -8 -8 -8 
Plicamycin -8 N/A N/A 
Bleomycin sulfate -5.5 -5.2 -4.1 
Vinorelbine tartrate -8 N/A -7.7 
Temsirolimus  -8 -8 -5.6 
Gemcitabine hydrochloride -8 -5.9 -6 
Imiquimod  -4.5 -4.4 -4.3 
Plerixafor  -4 -4 -4 
Dacarbazine   -4.1 -4 -4 
Arsenic trioxide -4.2 -4 -4 
Triethylenemelamine -5.6 -5.1 -4.6 
Carboplatin   -3.9 -3.6 -3.6 
Erlotinib hydrochloride -4 -5.4 -5.2 
Amifostine -3.1 N/A N/A 
Zoledronic acid -4.1 -4.1 -4.4 
Oxaliplatin   -6.6 -5.7 -4 
Melphalan hydrochloride -5.2 N/A N/A 
Abiraterone N/A N/A -5.1 
 
Figure 11. GI50 values of approved oncology drugs for three breast cancer cell lines. 
 
The second growth inhibition value identified was the TGI value. This is the 
concentration that shows no net growth over the course of the assay and can also 
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DRUG NAME MCF-7 T47D MDA-MB-231 
Hydroxyurea -2.6 N/A -2.6 
Allopurinol -2.3 -2.3 -2.8 
Fluorouracil -2.8 -2.7 -2.6 
Thioguanine -4.2 -4.1 -3.8 
Mercaptopurine -3.2 -3.1 -3.1 
Mechlorethamine hydrochloride -4.8 N/A -4.4 
Thiotepa -3.5 -3 -3.1 
Aminolevulinic acid hydrochloride -4 -4 -4 
Temozolomide   -4 -4 -4 
Busulfan -3.6 -3.6 -3.6 
Altretamine -3.8 N/A -3.8 
Floxuridine -2.6 -2.6 -2.6 
Methoxsalen -4 -4 -4 
Lomustine -3.9 N/A -5.5 
Azacitidine   -4 -5.2 -5.2 
Decitabine   -3.4 N/A -3.4 
Carmustine   -3.6 -3.6 -3.8 
Cyclophosphamide   -3.6 N/A -3.6 
Uracil mustard -3.7 N/A -3.7 
Cytarabine hydrochloride -3.3 -3.3 -3.3 
Thalidomide   -4 -4 -4 
Procarbazine hydrochloride -3.3 N/A -3.3 
Streptozocin -3.2 N/A -3.1 
Cladribine -4 -4 -4 
Ifosfamide -3.4 N/A -3.3 
Cisplatin -3.7 -3.6 -3.6 
Tretinoin -4 -4 -4 
Dexrazoxane -3.3 -3.4 -3.2 
Pentostatin -3.3 -3.3 -3.3 
Nelarabine   -2.3 -2.3 -2.3 
Vorinostat   -4.4 -5.4 -4 
Exemestane   -4.2 -4 -4 
Anastrozole   -2 -2 -2 
Letrozole   -2.3 -2.3 -2.3 
Lenalidomide   -4 -4 -4 
Pomalidomide -4 -4 -4 
Chlorambucil   -3.4 -3.4 -3.4 
Mitomycin  -5 -4.7 -4.6 
Mitotane -4.4 N/A -4.4 
Clofarabine   -4 -4 -4.6 
Pipobroman -3.7 N/A -3.7 
Megestrol acetate -4 -4 -4 
Bendamustine hydrochloride -4 -4 -4 
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Fludarabine phosphate   -3.1 -3.4 -2.9 
Bortezomib   -4 -8 -8 
Capecitabine  -2 -2 -2 
Celecoxib -4.5 -4.4 -4.5 
Sunitinib  -4.9 -4.5 -4.8 
Axitinib -4 -4.3 -4 
Mitoxantrone -6.2 -6 -5.8 
Pemetrexed -4 -4 -4 
Gefitinib   -4.6 -4.7 -4.6 
Vismodegib -4 -4 -4 
Crizotinib   -5.7 -5.5 -5.3 
Methotrexate   -3.6 -3.6 -3.6 
Topotecan hydrochloride -5.7 -6.4 -3.9 
Dasatinib   -4.5 -4.6 -5.5 
Pazopanib hydrochloride -4 -4.6 -4 
Imatinib -4.4 -4.2 -4.3 
Sorafenib -5 -5.2 -5.4 
Raloxifene -4.9 -4.3 -4.6 
Afatinib -5 -4.8 -5.2 
Pralatrexate   -4 -4 -4 
Enzalutamide  -4.2 -4 -4.4 
Vandetanib -4.8 -5.2 -5.3 
Vemurafenib   -4.8 -4.6 -4.8 
Regorafenib  -5.1 -5 -5.2 
Idarubicin hydrochloride -5.8 -6.7 -5.9 
Nilotinib  -5.1 -4.5 -4.8 
Ixabepilone  -8 -8 -8 
Romidepsin   -8 N/A -6.8 
Omacetaxine mepesuccinate -7.2 -6.6 -6.4 
Ponatinib  -5.7 -5.7 -6 
Cabozantinib  -4.3 -4 -4.4 
Bosutinib  -4.8 -4.7 -5.1 
Daunorubicin hydrochloride -5.4 -5.7 -6.1 
Doxorubicin hydrochloride -5 -6.1 -5.4 
Etoposide   -4 N/A N/A 
Tamoxifen citrate -5.2 -4.7 -4.8 
Epirubicin hydrochloride N/A -6.2 -5.2 
Estramustine phosphate sodium -4 -4 -4.2 
Lapatinib  -5.2 -4.4 -4.5 
Irinotecan hydrochloride -4 -4 -4 
Fulvestrant -4 -4 -4 
Trametinib  -4.2 -4.1 -4.9 
Dabrafenib mesylate -4 -4 -4.2 
Teniposide -4.8 N/A -5.3 
Valrubicin N/A -5.1 -4 
Carfilzomib  -5.3 -7.6 -7.2 
Docetaxel   -4.1 N/A N/A 
Cabazitaxel   -4.7 -4 -4.3 
Paclitaxel   -4.3 -4.2 -4.5 
Vinblastine sulfate   -4.3 -4.4 -6.3 
Vincristine sulfate   -4.2 -3.4 -6.3 
Sirolimus -4.7 -4.4 -4.6 
Everolimus   -4.9 -4.7 -4.6 
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Dactinomycin -8 -8 -7.3 
Plicamycin -4 N/A N/A 
Bleomycin sulfate -4 -4.3 -4 
Vinorelbine tartrate -4.9 -4.5 -5.1 
Temsirolimus  -4 -4 -4.5 
Gemcitabine hydrochloride -4 -4 -4 
Imiquimod  -4 -4 -4 
Plerixafor  -4 -4 -4 
Dacarbazine   -4 -4 -4 
Arsenic trioxide -4 -4 -4 
Triethylenemelamine -4.5 -4.1 -4.2 
Carboplatin   -3.6 -3.6 -3.6 
Erlotinib hydrochloride -4 -4 -4.4 
Amifostine -3.1 N/A N/A 
Zoledronic acid -4 -4 -4.2 
Oxaliplatin   -5.2 -4 -4 
Melphalan hydrochloride -4.3 N/A N/A 
Abiraterone -4 -4 -4 
 
Figure 12. TGI values of approved oncology drugs for three breast cancer cell lines. 
 
The last endpoint identified is the LC50 value, which calculates the concentration 
that promotes apoptosis in 50% of the cells present at the time of compound addition. 
These results are available in Figure 13. 
 
DRUG NAME MCF-7 T47D MDA-MB-231 
Hydroxyurea -2.6 N/A -2.6 
Allopurinol -2.3 -2.3 -2.3 
Fluorouracil -2.6 -2.6 -2.6 
Thioguanine -3.6 -3.6 -3.6 
Mercaptopurine -3.1 -3.1 -3.1 
Mechlorethamine hydrochloride -3.8 N/A -3.9 
Thiotepa -3.1 -3 -3 
Aminolevulinic acid hydrochloride -4 -4 -4 
Temozolomide   -4 -4 -4 
Busulfan -3.6 -3.6 -3.6 
Altretamine -3.8 N/A -3.8 
Floxuridine -2.6 -2.6 -2.6 
Methoxsalen -4 -4 -4 
Lomustine -3.5 N/A -3.6 
Azacitidine   -3.6 -3.6 -3.7 
Decitabine   -3.4 N/A -3.4 
Carmustine   -3.6 -3.6 -3.6 
Cyclophosphamide   -3.6 N/A -3.6 
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Uracil mustard -3.3 N/A -3.3 
Cytarabine hydrochloride -3.3 -3.3 -3.3 
Thalidomide   -4 -4 -4 
Procarbazine hydrochloride -3.3 N/A -3.3 
Streptozocin -3.2 N/A -3.1 
Cladribine -4 -4 -4 
Ifosfamide -3.3 N/A -3.3 
Cisplatin -3.3 -3.3 -3.3 
Tretinoin -4 -4 -4 
Dexrazoxane -2.8 -2.9 -2.9 
Pentostatin -3.3 -3.3 -3.3 
Nelarabine   -2.3 -2.3 -2.3 
Vorinostat   -4 -4 -4 
Exemestane   -4 -4 -4 
Anastrozole   -2 -2 -2 
Letrozole   -2.3 -2.3 -2.3 
Lenalidomide   -4 -4 -4 
Pomalidomide -4 -4 -4 
Chlorambucil   -3.1 -3.2 -3.2 
Mitomycin  -4.6 -4.6 -4.6 
Mitotane -4.1 N/A -4.2 
Clofarabine   -4 -4 -4 
Pipobroman -3.4 N/A -3.5 
Megestrol acetate -4 -4 -4 
Bendamustine hydrochloride -4 -4 -4 
Fludarabine phosphate   -2.9 -2.9 -2.9 
Bortezomib   -4 -5 -4.4 
Capecitabine  -2 -2 -2 
Celecoxib -4.2 -4.1 -4.3 
Sunitinib  -4.3 -4.1 -4.4 
Axitinib -4 -4 -4 
Mitoxantrone -5.3 -5.1 -5 
Pemetrexed -4 -4 -4 
Gefitinib   -4.3 -4.2 -4.3 
Vismodegib -4 -4 -4 
Crizotinib   -5.3 -5.1 -4.8 
Methotrexate   -3.6 -3.6 -3.6 
Topotecan hydrochloride -3.9 -3.9 -3.9 
Dasatinib   -4.1 -4 -4.4 
Pazopanib hydrochloride -4 -4 -4 
Imatinib -4.1 -4 -4 
Sorafenib -4.1 -4.1 -4.7 
Raloxifene -4.3 -4.1 -4.2 
Afatinib -4.4 -4.3 -4.4 
Pralatrexate   -4 -4 -4 
Enzalutamide  -4 -4 -4 
Vandetanib -4.4 -4.5 -4.8 
Vemurafenib   -4.3 -4.1 -4.2 
Regorafenib  -4.1 -4 -4 
Idarubicin hydrochloride -4.7 -4.4 -4.9 
Nilotinib  -4.2 -4.1 -4.3 
Ixabepilone  -8 -8 -8 
Romidepsin   -5.8 -4.1 -5.3 
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Omacetaxine mepesuccinate -4 -4 -4 
Ponatinib  -5.3 -5.2 -5.4 
Cabozantinib  -4 -4 -4 
Bosutinib  -4.3 -4.3 -4.6 
Daunorubicin hydrochloride -4.6 -4.3 -5 
Doxorubicin hydrochloride -4.3 -4.1 -4.5 
Etoposide   -3.4 N/A N/A 
Tamoxifen citrate -4.6 -4 -4.3 
Epirubicin hydrochloride N/A -4 -4.6 
Estramustine phosphate sodium -4 -4 -4 
Lapatinib  -4.6 -4 -4.2 
Irinotecan hydrochloride -4 -4 -4 
Fulvestrant -4 -4 -4 
Trametinib  -4 -4 4.2 
Dabrafenib mesylate -4 -4 -4 
Teniposide -4.6 N/A -4.6 
Valrubicin N/A -4 -4 
Carfilzomib  -4 -4.9 -4.1 
Docetaxel   -4 N/A -4 
Cabazitaxel   -4 -4 -4 
Paclitaxel   -4.1 -4 -4.1 
Vinblastine sulfate   -4 -4.1 -4.5 
Vincristine sulfate   -3.4 -3.1 -4 
Sirolimus -4.2 -4.1 -4.2 
Everolimus   -4.4 -4 -4.2 
Dactinomycin -4 -4 -4 
Plicamycin -4 N/A N/A 
Bleomycin sulfate -4 -4 -4 
Vinorelbine tartrate -4.3 -4 -4.3 
Temsirolimus  -4 -4 -4 
Gemcitabine hydrochloride -4 -4 -4 
Imiquimod  -4 -4 -4 
Plerixafor  -4 -4 -4 
Dacarbazine   -4 -4 -4 
Arsenic trioxide -4 -4 -4 
Triethylenemelamine -4.2 -4 -4 
Carboplatin   -3.6 -3.6 -3.6 
Erlotinib hydrochloride -4 -4 -4 
Amifostine -3.1 N/A N/A 
Zoledronic acid -4 -4 -4.1 
Oxaliplatin   -4 -4 -4 
Melphalan hydrochloride -4 N/A N/A 
Abiraterone -4 -4 -4 
 
Figure 13: LC50 values of approved oncology drugs for three breast cancer cell 
lines. 
 
II. Screening Data 
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National Cancer Institute 
 
 The results of the 60-cell line assay suggested the need for further screening in 
order to determine which cell line to proceed with in the experiment. As mentioned 
previously, the MDA-MB-231, T47D, and MCF-7 cell lines were screened, along with 
the LM, BoM, and BrM-2a metastatic sites of MDA-MB-231. The results are represented 




Figure 14: Screening Data of Compounds at 1 µM 
 
Due to a large variation value for MDA-MB-231, some of the data was missing 
throughout the screening process because of its unreliability. However, it was decided to 
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III. Pilot Experiment with BoM 
 Besides the primary goal of the pilot experiment to familiarize oneself with the 
techniques and procedures of cell viability, the results remain relevant in the study. After 
the two-day assay with BoM, the percent control for both compounds was calculated at 
the various concentrations based on the plate readout. The results were compared to the 
media control and the positive CHX control in order to determine relevant cytotoxicity. 
The results of BoM with phenformin are shown in Figure 15. 
 
 
Figure 15: Effects of Phenformin on BoM in Pilot Experiment 
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 From the results, it can be seen that BoM was subject to the most inhibition at 30 
µM, as its final cellular concentration was closest to the cellular concentration of the 
CHX control. Although there is evidence of this inhibition, it is as a concentration higher 
than the physiologically relevant range of 30 µM, so it is not necessarily applicable in 
clinical settings for cancer treatment due to the body’s inability to tolerate the compound 
at such a high concentration. However, there is evidence of slight inhibition at the 
concentration of 3 µM, which could prove more relevant in an experiment with longer 
cell viability duration. 




Figure 16: Effects of Metformin on BoM in Pilot Experiment 
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In this graph, it can be seen that the most inhibition occurred with metformin at 30 
µM and 100 µM. These results are more clinically relevant than the results for 
phenformin, as the physiological relevant concentration of metformin is 30 µM.  
Although the pilot experiment was to practice protocol and technique, the results 
did suggest that both phenformin and metformin show some range of inhibition when 
exposed to the BoM cell line. In order to further explore this observation, results were 
gathered from the two day and five day assays with MDA-MB-231, LM, and BoM cell 
lines.  
 
IV. Two-Day Viability Study with MDA-MB-231, LM, and BoM 
 After processing the plate readout from the two-day assays, graphs were created 
to compare compound inhibition. The results follow in Figure 17 and Figure 18. 
 
 
Figure 17: Effects of Phenformin on MDA-MB-231 in Two-Day Viability Study 
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Figure 18: Effects of Metformin on MDA-MB-231 in Two-Day Viability Study 
 
These results from the treatment of MDA-MB-231 did not show significant 
amounts of inhibition, however slight evidence of cellular cytotoxicity did exist. The 
highest inhibitory value when treated with phenformin was seen at 30 µM, which is 
physiologically irrelevant, and slight inhibition was seen at concentrations of 3 µM, 0.1 
µM, and 0.03 µM. When the cell line was treated with metformin, slight inhibition was 
noted at concentrations of 30 µM, 3 µM, and 1 µM. All of these concentrations would be 
physiologically relevant and were suspected to become more pronounced in a viability 
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The data was then processed for compound effects on LM. The results are 
represented in Figure 19 and Figure 20.  
 




Figure 20: Effects of Metformin on LM in Two-Day Viability Study 
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Phenformin and Metformin did not show much inhibition on the LM cell line. 
Phenformin was most active at concentration of 0.03 µM and 0.1 µM, which are 
extremely low concentrations. Metformin showed slight inhibition at 3 µM, which is 
closer to the physiological relevant range of the compound and suggests slightly more 
conclusive results.  
The results for BoM during the two-day viability study are represented in Figure 
21 and Figure 22. 
 
 
Figure 21: Effects of Phenformin on BoM in Two-Day Viability Study 
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Figure 22: Effects of Metformin on BoM in Two-Day Viability Study 
 
As with the two-day viability, phenformin was most active at a concentration of 
30 µM for BoM, which is too high physiologically. Metformin showed the most 
inhibition at high concentrations of 100 µM and 300 µM, however evidence of slight 
inhibition did exist at more relevant concentrations of 10 µM and 30 µM. 
 All of these results from the two-day concentration response viability study 
showed very small effects of phenformin and metformin on the three cell lines. However, 
effects were present which again suggests that the two compounds do have some sort of 
inhibitory effect on breast cancer cells. It was suspected that the lack of significant 
inhibitory effects seen in this part of the experiment was due to such a short period of 
compound exposure. In order to explore this possibility, the results were interpreted for 
the five-day viability study in order to determine if a longer exposure to the compounds 
would increase cellular inhibition. 
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V. Five-Day Viability Study with MDA-231, LM, and BoM 
 Upon adding in compounds to the 96 well plates during the five-day viability 
study, it was noted that MDA-MB-231 and BoM cell lines appeared stressed, so it was 
predicted that the results for these two cell lines would not be extremely reliable. 
However, the experiment was done to completion, as the LM cell line appeared healthy 
during each step of the experiment. For this reason, the graphic results for LM are more 
reliable in this particular study than for the other two cell lines. Phenformin effects on 
MDA-MB-231 are represented in Figure 23. 
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The effects of metformin on this cell line is represented by Figure 24.  
 
 
Figure 24: Effects of Metformin on MDA-MB-231 in Five-Day Viability Study 
 
 Concurrent with the results of the two-day study, phenformin inhibited the MDA-
MB-231 cell lines at 0.03 µM and 0.1 µM. However, increased compound exposure did 
not significantly increase the inhibitory effects at concentrations of 3 µM and 30 µM. The 
inconsistency of these results can be attributed to the stressed appearance of the cells 
prior to compound addition. When treated with metformin, however, the cells showed 
inhibition at all concentrations. This suggests the potency of metformin, especially 
because the most inhibition was noted at 3 µM and 30 µM, which is consistent with 
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The results for phenformin and metformin with cell line BoM are represented by Figure 
25 and Figure 26.  
 
 
Figure 25: Effects of Phenformin on BoM in Five-Day Viability Study  
 
 
Figure 26: Effects of Metformin on BoM in Five-Day Viability Study 
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 The greatest inhibition of BoM when treated with phenformin is seen at 3 µM, 
which is completely concurrent with the known physiological relevant concentration. 
This suggests the effectiveness of treatment with phenformin for patients with breast 
cancer metastasis to the bone. When treated with metformin, the most inhibition is noted 
at 1 µM, 3 µM, and 30 µM, which is a range that leads directly to the most relevant 
concentration. This also suggests the effectiveness of metformin in this particular case of 
metastasis. The last set of results for the five-day viability study is shown in Figure 27 
and Figure 28. 
 
 
Figure 27: Effects of Phenformin on LM in Five-Day Viability Study 
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Figure 28: Effects of Metformin on LM in Five-Day Viability Study 
 
 When treated with phenformin, the LM cell line showed the most significant 
inhibition from a range of 0.3 µM to10 µM, which encompasses the physiologically 
relevant concentration of 3 µM. When treated with metformin, the most inhibition was 
noted at 3 µM, which is significantly more pronounced in the five-day study in 
comparison to the two-day study. All of these results suggest that the increased time of 
exposure to the compounds increased the accuracy and significance of the results. 
 Although the results for MDA-MB-231 and BoM were not as reliable due to the 
conditions of their experimentation, the results of all three cell lines conclusively show 
that phenformin and metformin have inhibitory effects around the physiological relevant 
concentrations for each particular cell line, and that longer exposure to the compounds 
results in greater rates of cell death.  
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VI. Clonogenic Assay 
 After staining the clonogenic assay plates, the plates were compared in order to 
determine what affect the compounds had on suppressing colony formation in the various 
cell lines. The results are as follows in Figure 29: 
 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Phenformin:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Metformin:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Media	  	  	  	  	  	  	  	  	  	  	  	  CHX	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  µM         10 µM         30 µM        100 µM	  
	  
	  	   	  	   	  	   	  	   	  	   	  
	  
	  
	  	  	  	  	  	  	   	  	   	  	   	  	   	  	   	  	   	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	   	  	   	  	   	  	   	  	   	  	   	  
	  
Figure	  29:	  Effects	  of	  Phenformin	  and	  Metformin	  on	  Colony	  Formation	  
 
 
 To interpret these results, we compared the concentration of colonies in each 
compound treatment well to the media control in order to determine if any inhibition or 
cytotoxicity occurred. Interpreting the result, there are some signs of inhibition with 
metformin at the higher concentration compared to the media control, especially with 
BoM. This would suggest that metformin, at a concentration of 100 µM shows 
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slight evidence of inhibition for phenformin at a concentration of 10 µM when MDA-
MB-231 was treated with phenformin. Due to the possibility of contamination while 
performing the experiments, the ten-day compound exposure was shortened to eight days, 
which may be responsible for the lack of inhibitory differences seen in all wells. 
However, the results do suggest that these compounds have the ability to suppress colony 
formation at higher concentrations and that further research into the mechanisms of these 
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DISCUSSION AND CONCLUSION 
 
 Metastatic breast cancer is an extremely invasive and unpredictable disease that 
affects an estimated 162,000 women in the United States every year (Komen, 2016). 
Although technology and funding focusing on lowering this number has increased 
throughout recent years, the survival rate for metastatic breast cancer remains at a mere 
26%. This has increased the need for new compounds and methods of treatment (Komen 
2016). After researching and screening current approved oncology drugs with different 
cell lines and expected metastatic sites, phenformin and metformin were chosen as 
possibilities to explore in order to suppress breast cancer metastasis and increase survival 
rate. The cell lines MDA-MB-231, LM, and BoM were treated with these compounds at 
various concentrations in a series of viability studies in order to determine their ability to 
serve as an organ-selective anti-metastatic therapeutic treatment.  
 In order to determine this ability of the compounds, the level of inhibition must be 
compared to the physiological relevant concentration for each individual compound. If 
high levels of inhibition exist but it is at a concentration higher than the human body can 
tolerate, then it is not relevant information for patient treatment. This was taken into 
consideration while processing the results in order to obtain the most relevant conclusion. 
Collectively, the data for the pilot experiment with BoM as well as the data with 
all cell lines for the two-day viability study suggested similar results. The highest levels 
of inhibition were noted with the compound phenformin, although the particular
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concentration differed for each cell line. Although this high level of inhibition initially 
seemed promising, the concentrations it presented at was generally always higher than 
the physiological relevant concentration of 3 µM, as it normally showed significant 
results at concentrations of 30 µM. Metformin, however, caused inhibitory effects on all 
cell lines in these experiments at or near its physiological relevant concentration of 30 
µM. From these results, it seemed reasonable to suggest that while phenformin may have 
a more potent effect on the breast cancer cells, metformin may serve as a better treatment 
option due to its consistency to suppress growth at concentrations tolerable to patients. 
However, the increased duration of compound exposure during the five-day assay was 
critical to confirm this.  
The results of the five-day viability study were less reliable than hoped due to 
cellular stress and the possibility of contamination. However, interesting results were 
noted for both phenformin and metformin. The inhibitory effects of phenformin seemed 
to close in on its relevant concentration when exposed to the compounds for a longer 
period of time for metastatic cell lines LM and BoM. During the two-day study, as well 
as the five-day study for MDA-MB-231, the greatest inhibitory effects of phenformin 
were seen at concentrations below or above the necessary concentration. However, when 
exposed to the compounds for a longer duration, significant inhibition was seen at 3 µM 
for LM and BoM. Although initially it was suggested that phenformin was more potent 
but less clinically relevant, further research could show that phenformin does in fact 
become more clinically relevant when compound exposure time increases.  
Another interesting result of the five-day assay was increased inhibitory nature of 
metformin in comparison to the two-day study. This result can be most clearly 
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demonstrated with LM, as it offered the most reliable results in the five-day study. After 
the initial experiment, LM only experienced a 5% inhibition when treated with 
metformin. However, after the longer duration of the next experiments, LM experienced 
a 24% inhibition. This suggests that a longer duration of compound exposure actually 
increased the inhibitory effects that metformin has on proliferating breast cancer cells.  
One theory behind this is due to the metabolism mechanism that LM cells rely on. 
In order to catabolize nutrients, LM cells typically rely on oxidative 
phosphorylation, which occurs in the mitochondria. For this reason, techniques to 
suppress cell growth are aimed at mitochondrial inhibitors, which typically take a longer 
period of time to show effect (Ramsay, 2011). This is why the results for LM were 
drastically different between a period of two days and five days; the compound simply 
needed more time to disrupt the mitochondrial metabolism of the LM cells and suppress 
the cell growth. This is in contrast to cell lines such as BoM, which rely on glycolysis in 
order to proliferate. This cell line would in theory not need as much time to become 
affected by the compound due to its lack of extreme dependence on the mitochondria in 
comparison to LM (Ramsay, 2011). Unfortunately, due to the stressed nature of the BoM 
cells, the results are not conclusive enough to suggest a mechanism.  
In conclusion, the results of these experiments offer much insight into the potency 
of these compounds as potential therapeutic agents for breast cancer and breast cancer 
metastasis. The various cell lines, compounds, and viability durations allowed a range of 
results to interpret and apply. Overall, these experiments conclude that phenformin was a 
generally more potent inhibitory agent, but that it is less clinically relevant due to its 
inconsistency to act at a concentration relevant to human physiology at multiple exposure 
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lengths. It can also be stated that metformin offered more conclusive results, as it was 
shown to increase inhibitory effects proportional to increased exposure length, as in the 
case with LM due to mitochondrial inhibition. Metformin also offered the most consistent 
levels of inhibition throughout all parts of this research, including the pilot experiment, 
two-day viability, five-day viability, and clonogenic assay. This conclusively suggests 
that metformin, at this time, would be the best compound to act as an organ-selective 
anti-metastatic therapeutic treatment option for triple-negative breast cancer. Further 
research would be needed in order to extrapolate from these ideas and hopefully provide 
a treatment option that would significantly increase the survival rate of patients by 
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